Pregledni rad
ANTI –TNF THERAPY IN INFLAMMATORY BOWEL DISEASES DURING PREGNANCY AND BREAST-FEEDING
MLADEN PERŠIĆ
; Klinika za dječje bolesti, Klinički bolnički centar Rijeka, Medicinski fakultet, Sveučilište u Rijeci, Rijeka, Hrvatska
Sažetak
Since the early occurrence of inflammatory bowel diseases in young people, the role of pregnancy on disease course, and the influence of different therapies on pregnancy, fetal development and the safety of breastfeeding have been one of the important questions. Biological therapy has been increasingly used and all the above mentioned questions seem to be of a great interest. The majority of research indicate that the possibility of conception in patients with IBD are the same as in a healthy population, although there is an increased risk for the child in terms of prematurity or low birth weight. Pregnancy in IBD patient should be considered as a high risk. Most medications used to achieve or maintain remission are safe in pregnancy and breastfeeding. Exceptions are thalidomide and methotrexate that are absolutely contraindicated. Anti-TNF drugs are safe but it is advised to stop the treatment after 30-32 weeks of pregnancy due to the possibility of placental transfer of medications. Infliximab is excreted into breast milk in small quantities and breastfeeding is assumed to be safe. Pregnancy in IBD patients should be planned in advance so that the medications that are contraindicated could be excluded on time and further possible complication could be prevented by constant monitoring of pregnancy. Prospective studies of monitoring hroughout pregnancy and short-term and long-term forecasts of development of children whose mothers were pregnant when suffered from inflammatory bowel disease are necessary.
Ključne riječi
inflammatory bowel disease; anti TNF therapy; pregnancy; breast-feeding
Hrčak ID:
111689
URI
Datum izdavanja:
28.11.2013.
Posjeta: 1.942 *